The Angeles Clinic featured at ASCO 2013
Paradigm-shifting therapy for all solid tumors
Immunotherapy, specifically immune checkpoint inhibitors targeting the PD-1/PD-l1 pathway, took center stage at ASCO. The Arie Crown theatre was the site of the Clinical Science Symposium in relation to these paradigm-shifting therapies where nearly 1,500 physicians, nurses, and collaborators were packed to hear about the therapies that would help not only melanoma patients but also those with lung, renal, ovarian and a host of other carcinomas.
The Angeles Clinic and Research Institute has been involved with PD-1/PD-L1 antibodies since their inception. We were the first to have the drug deemed by the FDA to be a “breakthrough” therapy, Lambrolizumab(MK-3475), available for our patients. This data was presented and simultaneously published in the New England Journal of Medicine (Hamid et al.). Dr. Hamid then presented ground breaking data with anti-PDL1 antibody MPDL328A in melanoma. We are currently accruing to a study of this agent in combination with the BRAF inhibitor vemurafenib.
Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center presenting data of the combination of the Anti-PD-1 antibody nivolumab in combination with Ipilimumab. This was also simultaneously presented in the NEJM. Much has been made of the data presented which showed high reponse rates with PD-1 directed therapy. We are proud to be the first site in the United States with the ability to offer this therapy (Ipilimumab and Nivolumab combination) to our patients through a major phase III collaborative effort. (Wolchok et al) The data is promising. So too is the fact that we have these first-in-class paradigm-shifting therapeutics available for our patients at The Angeles Clinic and Research Institute.
Data presented at International Melanoma Congress
Data from Melanoma specific clinic trials performed at The Angeles Clinic and Research Institute are currently being presented at the 2012 Society of Melanoma Research meeting in Hollywood, CA. Information gathered from trials looking at parp inhibition, braf and mek combinatorial therapy, immunotherapeutics including PD-1 targeted antibody will be presented; these trials were available through the Clinical Research Program at The Angeles Clinic. Additional data on upcoming therapeutics including immunotherapeutics and targetted therapy (nras, PI3K) will be discussed. Dr. Hamid, Director of the Melanoma Program, will be presenting data form the MK-3475 anti-PD-1 antibody on Sunday November 11 as a LATE BREAKING ABSTRACT.
Angeles Clinic featured in ASCO POST
Featured in the American Society of Clinical Oncology (ASCO) Post - Dr. Hamid, Director of the Melanoma Program at The Angeles Clinic, discusses state of the art adjuvant and metastatic therapy for malignant melanoma.
- State of the art Therapy 2011
Data presented at International Melanoma Congress
Data from Melanoma clinic trials performed at The Angeles Clinic and Research Institute are currently being presented at the 2011 Society of Melanoma Research meeting in Tampa, FL. Information gathered from trials looking at parp inhibition, braf and mek combinatorial therapy, and tasisulam chemotherapeutics will be presented; all were available through the Clinical Research Program at The Angeles Clinic. Additional data on upcoming therapeutics including immunotherapeutics (PD-1) and targetted therapy (nras, PI3K) will be discussed.
Phase 1 Clincal Program expands at The Angeles Clinic
Success developing targeted therapies in oncology depends on the ability to identify new targets and develop agents that hit those targets in an efficient manner. Major clinical advances in the care of common cancers have been made through participation of patients in Phase I clinical trials of agents that achieve this goal. Predictive oncology biomarkers - i.e., genes and genetic mutations, proteins and signalling pathways implicated in the proliferation and death of cancer cells - and their use to control tumor growth has been a major advancement allowing more efficacious therapy with decreased toxicity. Our collaboration with pharmaceutical partners has been instrumental in bringing this care to our patients.
Click above for article
FDA Approves YERVOY™ For The Treatment of Melanoma
Click here for more information
The Angeles Clinic Plays A Major Role in FDA Approval
Click here for more information
Current and Future Clinical Trials
Click here for more information
News May 2010
Dr. Cathie Chung Joins Breast Program at The Angeles Clinic May 2009
The Angeles Clinic and Research Institute is pleased to announce the recruitment of Dr, Cathie Chung to join the Breast Cancer Program. Dr. Chung comes from a similar position at The City of Hope Cancer Center.
Dr. Chung brings her expertise in novel biologic therapeutics and targeted agents to strengthen the Clinical Trial Program at The Angeles Clinic. Her basic science interest is involved with in biological treatment manipulations that interfere with how a cancer develops and grows. Her addition to the Breast and Women’s Cancers Program will ensuring that our patients will benefit from state of the art, paradigmchanging therapies that have progressed from the clinical laboratory to the bedside.
Dr. Chung has been recognized by her peers for her dedication to patient care. Always the first in the clinic and the last one to go home, she has been received multiple awards for excellence as a teacher and mentor to physicians training for a career in medical oncology.
Dr. Chung’s resume relates a career of contribution dedicated to the advancement of cancer care in academia and in the community. She began her career in Medical Oncology at Stanford University after completing fellowship training there.
Adding to her expertise in clinical care is a PhD in Physiology obtained at the University of Illinois.
We look forward to the Dr. Chung’s collaboration with Dr. Silvano Martino at The Angeles Clinic and Research Institte. To schedule an appointment with Dr Chung, call (310) 582-7900.
View Current Newsletter - pdf version
